Nimbolide induces ROS-regulated apoptosis and inhibits cell migration in osteosarcoma

41Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Osteosarcoma (OS) is a primary malignant tumor of bone and is most prevalent in children and adolescents. OS is frequently associated with pulmonary metastasis, which is the main cause of OS-related mortality. OS has a poor prognosis and is often unresponsive to conventional chemotherapy. In this study, we determined that Nimbolide, a novel anti-cancer therapy, acts by modulating multiple mechanisms in osteosarcoma cells. Nimbolide induces apoptosis by increasing endoplasmic reticulum (ER) stress, mitochondrial dysfunction, accumulation of reactive oxygen species (ROS), and finally, caspase activation. We also determined that Nimbolide inhibits cell migration, which is crucial for metastasis, by reducing the expression of integrin αvβ5. In addition, our results demonstrate that integrin αvβ5 expression is modulated by the PI3K/Akt and NF-κB signaling cascade. Nimbolide has potential as an anti-tumor drug given its multifunctional effects in OS. Collectively, these results help us to understand the mechanisms of action of Nimbolide and will aid in the development of effective therapies for OS.

Cite

CITATION STYLE

APA

Liu, J. F., Hou, C. H., Lin, F. L., Tsao, Y. T., & Hou, S. M. (2015). Nimbolide induces ROS-regulated apoptosis and inhibits cell migration in osteosarcoma. International Journal of Molecular Sciences, 16(10), 23405–23424. https://doi.org/10.3390/ijms161023405

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free